Teclistamab in Practice: Real-World Efficacy and Infection Risks

EP: 1.Understanding REALiTEC: Real-World Insights on BCMA Bispecifics

Now Viewing

EP: 2.Teclistamab in Practice: Real-World Efficacy and Infection Risks

Clinical experience with teclistamab has largely aligned with findings from both clinical trials and real-world studies, demonstrating robust efficacy in relapsed/refractory multiple myeloma. Response rates, depth of remission, and durability have been consistent and impressive, reaffirming its value in clinical practice. For many patients, the outcomes observed in day-to-day settings are comparable to those reported in formal studies, validating teclistamab as a highly effective treatment option even outside controlled trial environments.

Initially, infection risk was a major concern, especially during the COVID-19 pandemic when many trials were conducted. The overlap between trial enrollment and peak pandemic periods likely contributed to a higher incidence of infections observed early on. However, newer analyses and meta-analyses have shown that teclistamab may carry a relatively lower risk of infections compared to other bispecific antibodies. This development, coupled with improved infection management strategies, has significantly enhanced the safety profile of the drug in real-world use.

Supportive care measures have evolved in parallel with the broader adoption of bispecific therapies. Most patients now receive comprehensive prophylactic regimens, including antivirals, antibiotics, and antifungals, in addition to immunoglobulin replacement when necessary. Routine vaccinations and vigilant monitoring for early signs of infection have also become standard practice. These improvements in clinical protocols have played a critical role in mitigating infection-related complications, making bispecific antibody therapies like teclistamab safer and more accessible for a broader range of patients. Overall, the combination of clinical experience and optimized supportive care has cemented teclistamab’s role in managing advanced multiple myeloma.